| Literature DB >> 28382308 |
Cheick O Guinto1, Salimata Diarra1, Salimata Diallo2, Lassana Cissé1, Thomas Coulibaly1, Seybou H Diallo2, Abdoulaye Taméga1, Ke-Lian Chen3, Alice B Schindler3, Koumba Bagayoko1, Assiatou Simaga4, Craig Blackstone3, Kenneth H Fischbeck3, Guida Landouré5.
Abstract
Hereditary spastic paraplegias (HSPs) are well-characterized disorders but rarely reported in Africa. We evaluated a Malian family in which three individuals had HSP and distal muscle atrophy and sensory loss. HSP panel testing identified a novel heterozygous missense mutation in KIF5A (c.1086G>C, p.Lys362Asn) that segregated with the disease (SPG10). Lys362 is highly conserved across species and Lys362Asn is predicted to be damaging. This study shows that HSPs are present in sub-Saharan Africa, although likely underdiagnosed. Increasing efficiency and decreasing costs of DNA sequencing will make it more feasible to diagnose HSPs in developing countries.Entities:
Year: 2017 PMID: 28382308 PMCID: PMC5376762 DOI: 10.1002/acn3.402
Source DB: PubMed Journal: Ann Clin Transl Neurol ISSN: 2328-9503 Impact factor: 4.511
Figure 1Pedigree of the family showing the autosomal dominant inheritance pattern. Individuals with Hereditary spastic paraplegias (HSP) phenotype (solid black) and individuals with SCA (solid gray) are indicated. The arrow identifies the proband. Ages at examination are shown at the top of each symbol, and asterisks (*) identify those seen in clinic.
Phenotypic characteristics of subjects with SPG10
| Patient | Clinical and demographic features | Nerve conduction studies | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (year) | Sex | Age of onset (year) | First symptom | Spasticity | Distal leg weakness and atrophy | Sensory loss | Left median | Sural | Peroneal | Tibial | ||||||||||
| Right | Left | Right | Left | |||||||||||||||||
| CMAP Amp (mV) | CV m/sec | SNAP Amp | CMAP Amp (mV) | CV m/sec | CMAP Amp (mV) | CV m/sec | F wave (msec) | CMAP Amp (mV) | CV m/sec | CMAP Amp (mV) | CV m/sec | F wave (msec) | ||||||||
| III.3 | 68 | M | ~20 | Walking difficulty | Yes | Moderate | Moderate | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| IV.9 | 23 | M | 10 | Walking difficulty | Yes | Moderate | Moderate | 17.5 | 57 | 26 | 9.7 | 45 | 9 | 46 |
| 5.2 |
| 6.4 |
|
|
| IV.10 | 21 | M | 11 | Walking difficulty | Yes | Mild | Mild | 12.1 | 60 | 29 | 15 | 46 | 13.7 | 47 | 52 | 10.2 | 43 | 11.4 | 44 |
|
Amp, amplitude; SNAP, sensory nerve action potential; CMAP, compound motor action potential; ND, not done; CV, conduction velocity, normal median CMAP>4.5 mV (recorded at abductor pollicis brevis muscle), normal peroneal CMAP>2.5 mV (recorded at extensor digitorus brevis muscle), normal tibial CMAP>6 mV (recorded at abductor hallucis muscle), normal sural SNAP>10 μV, normal F wave<55 msec.
Figure 2Electropherograms of the novel sequence variant. Sanger DNA sequencing shows an unaffected family member to be homozygous (G/G; panel A), while the affected individual is heterozygous (G/C), for the pathogenic variant (denoted by *; panel B). Protein sequence alignment of in various species (amino acid numbers refer to the human sequence). The SPG10 mutation causes an amino acid change at Lys362, a highly conserved residue (in red, asterisk above, panel C).